Stemline Therapeutics Announces Presentation of SL-801 and SL-701 Clinical Data at the Upcoming ASCO Annual Meeting
NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that clinical data from SL-801 and SL-701 trials have been selected for …